Among cAMP-modulating agents already approved for clinical use are PDE4 inhibitors and β2AR agonists, which are used for chronic obstructive pulmonary disease (COPD) and asthma [70], respectively, and could be repurposed for CF treatment. The gene discussed is PDE4A; the disease is cystic fibrosis.